RU2006116890A - Производные n-[фенил(пирролидин-2-ил)метил]бензамида и n-[(фзепан-2-ил)фенилметил]бензамида, способ их получения и их применение в терапии - Google Patents
Производные n-[фенил(пирролидин-2-ил)метил]бензамида и n-[(фзепан-2-ил)фенилметил]бензамида, способ их получения и их применение в терапииInfo
- Publication number
- RU2006116890A RU2006116890A RU2006116890/04A RU2006116890A RU2006116890A RU 2006116890 A RU2006116890 A RU 2006116890A RU 2006116890/04 A RU2006116890/04 A RU 2006116890/04A RU 2006116890 A RU2006116890 A RU 2006116890A RU 2006116890 A RU2006116890 A RU 2006116890A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- alkyl
- group
- configuration
- phenyl
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- GHAGJIFNBIGABU-UHFFFAOYSA-N n-[phenyl(pyrrolidin-2-yl)methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(C=1C=CC=CC=1)C1CCCN1 GHAGJIFNBIGABU-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims abstract 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 3
- -1 cyano, acetyl Chemical group 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 208000030814 Eating disease Diseases 0.000 claims abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000002877 Epileptic Syndromes Diseases 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000006111 contracture Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000001067 neuroprotector Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 2
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000002075 anti-alcohol Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000002460 anti-migrenic effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000000147 hypnotic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
- Соединение общей формулы (I):в которой n обозначает число 1 или 3,R1 обозначает либо атом водорода, либо прямую или разветвленную группу (С1-С7)алкил, возможно замещенную одним или несколькими атомами фтора, либо группу (С3-С7)циклоалкил, либо группу (С3-С7)циклоалкил(С1-С3)алкил, либо группу фенил(С1-С3)алкил, возможно замещенную одной или двумя метоксигруппами, либо группу (С2-С4)алкенил, либо группу (С2-С4)алкинил,X обозначает либо атом водорода, либо один или несколько заместителей, выбранных из атомов галогена и групп: трифторметил, прямые или разветвленные (С1-С6)алкилы и (С1-С6)алкоксилы,R2 обозначает либо атом водорода, либо один или несколько заместителей, выбранных из атомов галогена и групп: трифторметил, прямые или разветвленные (С1-С6)алкилы, (С1-С6)алкоксилы, (С3-С7)циклоалкилы, фенил, циано, ацетил, бензоил, S(C1-C6)алкилы, (С1-С6)алкилсульфонилы, карбокси и (С1-С6)алкоксикарбонилы, либо группу общей формулы NR3R4, SO2NR3R4 или CONR3R4, в которых R3 и R4 каждый, независимо друг от друга, обозначают атом водорода или прямую или разветвленную группу (С1-С6)алкил или группу (С3-С7)циклоалкил, или образуют вместе с атомом азота, с которым они соединены, цикл пирролидина, пиперидина или морфолина, в форме основания или аддитивной соли с кислотой.
- 2. Соединение по п.1, отличающееся тем, что оно имеет относительную конфигурацию трео (1S, 2S; 1R, 2R).
- 3. Соединение по п.1, отличающееся тем, что оно имеет конфигурацию (1S, 2S).
- 4. Соединение по п.1, отличающееся тем, что оно имеет конфигурацию (1R, 2R).
- 5. Соединение по п.1, отличающееся тем, что оно имеет относительную конфигурацию эритро (1S, 2R; 1R, 2S).
- 6. Соединение по п.1, отличающееся тем, что оно имеет конфигурацию (1R, 2S).
- 7. Соединение по п.1, отличающееся тем, что оно имеет конфигурацию (1S, 2R).
- 8. Лекарственное средство, отличающееся тем, что оно представляет собой соединение по любому из пп.1-5.
- 9. Фармацевтическая композиция, отличающаяся тем, что она содержит соединение по любому из пп.1-5, в сочетании с эксципиентом.
- 10. Применение соединения по п.1 для получения лекарственного средства, предназначенного для лечения поведенческих нарушений, ассоциированных с деменцией, психозов, различных форм страха, приступов паники, фобий, компульсивных навязчивых состояний, различных форм депрессии, нарушений, обусловленных злоупотреблением алкоголя или прекращением принятия алкоголя, нарушений сексуального поведения, нарушений приема пищи и для лечения мигрени.
- 11. Применение соединения по п.1 для получения лекарственного средства, предназначенного для лечения контрактур, боли, болезни Паркинсона и симптом болезни Паркинсона, эпилепсий, смешанных форм и других эпилептических синдромов в сочетании с другим антиэпилептическим лечением, или в монотерапии, для лечения апное во сне и в качестве нейропротектора.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0312143 | 2003-10-17 | ||
| FR0312143A FR2861070B1 (fr) | 2003-10-17 | 2003-10-17 | Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006116890A true RU2006116890A (ru) | 2007-11-27 |
| RU2386614C2 RU2386614C2 (ru) | 2010-04-20 |
Family
ID=34385236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006116890/04A RU2386614C2 (ru) | 2003-10-17 | 2004-10-15 | Производные n-[фенил(пирролидин-2-ил)метил]бензамида и n-[(азепан-2-ил)фенилметил]бензамида, способ их получения и их применение в терапии |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7226917B2 (ru) |
| EP (1) | EP1680400B1 (ru) |
| JP (1) | JP4700007B2 (ru) |
| CN (1) | CN1882534A (ru) |
| AT (1) | ATE364038T1 (ru) |
| AU (1) | AU2004281218B2 (ru) |
| BR (1) | BRPI0415511A (ru) |
| CA (1) | CA2542727A1 (ru) |
| CY (1) | CY1106827T1 (ru) |
| DE (1) | DE602004006891T2 (ru) |
| DK (1) | DK1680400T3 (ru) |
| ES (1) | ES2286689T3 (ru) |
| FR (1) | FR2861070B1 (ru) |
| HR (1) | HRP20070307T3 (ru) |
| IL (1) | IL174934A (ru) |
| MA (1) | MA28098A1 (ru) |
| ME (1) | MEP12608A (ru) |
| NO (1) | NO20062032L (ru) |
| NZ (1) | NZ547167A (ru) |
| PL (1) | PL1680400T3 (ru) |
| PT (1) | PT1680400E (ru) |
| RS (1) | RS20060315A (ru) |
| RU (1) | RU2386614C2 (ru) |
| WO (1) | WO2005037785A2 (ru) |
| ZA (1) | ZA200603862B (ru) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842804B1 (fr) | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861074B1 (fr) * | 2003-10-17 | 2006-04-07 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861070B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861071B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique |
| PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
| GB0612420D0 (en) * | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| US8420670B2 (en) | 2007-08-22 | 2013-04-16 | Abbott Laboratories | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| CN102083797B (zh) | 2008-04-01 | 2014-06-04 | Abbvie公司 | 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途 |
| US20120094995A1 (en) * | 2009-01-28 | 2012-04-19 | Astrazeneca Ab | 2-aza-bicyclo[2.2.1]heptane compounds and uses thereof |
| FR2941954B1 (fr) * | 2009-02-10 | 2011-04-08 | Sanofi Aventis | Derives de n-°(6-aza-bicyclo°3.2.1!oct-1-yl)-aryl-methyl! benzamide, leur preparation et leur application en therapeutique |
| FR2941953B1 (fr) * | 2009-02-10 | 2011-04-08 | Sanofi Aventis | Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-benzamide, leur preparation et leur application en therapeutique |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| JP2012520345A (ja) * | 2009-03-16 | 2012-09-06 | サノフイ | Ｎ−［（２−アザ−ビシクロ［２．１．１］ヘキス−１−イル）−アリール−）メチル］−ヘテロベンズアミドの誘導体、その調製および治療におけるその用途 |
| FR2943056A1 (fr) * | 2009-03-16 | 2010-09-17 | Sanofi Aventis | Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2014001457A (es) | 2011-08-05 | 2014-08-21 | Abbvie Deutschland | Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia. |
| CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN102692463A (zh) * | 2012-06-13 | 2012-09-26 | 山东凯盛新材料股份有限公司 | 高效液相色谱法检测芳香族酰氯类产品的方法 |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| AU2014336154A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| AU2014336153A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254569A (en) * | 1991-01-14 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | (Amidomethyl)nitrogen heterocyclic analgesics |
| JP3026845B2 (ja) * | 1991-02-20 | 2000-03-27 | 日清製粉株式会社 | ピペリジン誘導体 |
| AU3254499A (en) * | 1998-03-06 | 1999-09-20 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
| WO1999052519A2 (en) * | 1998-04-14 | 1999-10-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| FR2838739B1 (fr) * | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| FR2842804B1 (fr) * | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| FR2861070B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique |
| US8492418B2 (en) * | 2005-04-11 | 2013-07-23 | Yale University | Method of treating schizophrenia prodrome |
-
2003
- 2003-10-17 FR FR0312143A patent/FR2861070B1/fr not_active Expired - Fee Related
-
2004
- 2004-10-15 JP JP2006534801A patent/JP4700007B2/ja not_active Expired - Fee Related
- 2004-10-15 CN CNA2004800338510A patent/CN1882534A/zh active Pending
- 2004-10-15 DE DE602004006891T patent/DE602004006891T2/de not_active Expired - Lifetime
- 2004-10-15 PL PL04791555T patent/PL1680400T3/pl unknown
- 2004-10-15 ES ES04791555T patent/ES2286689T3/es not_active Expired - Lifetime
- 2004-10-15 RS YUP-2006/0315A patent/RS20060315A/sr unknown
- 2004-10-15 EP EP04791555A patent/EP1680400B1/fr not_active Expired - Lifetime
- 2004-10-15 ME MEP-126/08A patent/MEP12608A/xx unknown
- 2004-10-15 DK DK04791555T patent/DK1680400T3/da active
- 2004-10-15 AT AT04791555T patent/ATE364038T1/de active
- 2004-10-15 RU RU2006116890/04A patent/RU2386614C2/ru not_active IP Right Cessation
- 2004-10-15 BR BRPI0415511-4A patent/BRPI0415511A/pt not_active IP Right Cessation
- 2004-10-15 ZA ZA200603862A patent/ZA200603862B/en unknown
- 2004-10-15 WO PCT/FR2004/002644 patent/WO2005037785A2/fr not_active Ceased
- 2004-10-15 CA CA002542727A patent/CA2542727A1/fr not_active Abandoned
- 2004-10-15 HR HR20070307T patent/HRP20070307T3/xx unknown
- 2004-10-15 NZ NZ547167A patent/NZ547167A/en not_active IP Right Cessation
- 2004-10-15 AU AU2004281218A patent/AU2004281218B2/en not_active Ceased
- 2004-10-15 PT PT04791555T patent/PT1680400E/pt unknown
-
2006
- 2006-04-11 IL IL174934A patent/IL174934A/en not_active IP Right Cessation
- 2006-04-17 US US11/405,191 patent/US7226917B2/en not_active Expired - Fee Related
- 2006-04-17 MA MA28943A patent/MA28098A1/fr unknown
- 2006-05-05 NO NO20062032A patent/NO20062032L/no not_active Application Discontinuation
-
2007
- 2007-04-30 US US11/741,803 patent/US7700585B2/en not_active Expired - Fee Related
- 2007-08-31 CY CY20071101114T patent/CY1106827T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006116890A (ru) | Производные n-[фенил(пирролидин-2-ил)метил]бензамида и n-[(фзепан-2-ил)фенилметил]бензамида, способ их получения и их применение в терапии | |
| RU2006116886A (ru) | Производные n-[фенил(алкилпиперидин-2-ил]бензамида, их получение и их применение в терапии | |
| RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
| RU2006116889A (ru) | Производные n-гетероциклилметилбензамидов, их получение и их применение в терапии | |
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| WO2009035473A2 (en) | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| ES2222401T3 (es) | Derivados de piperazina, su preparacion y su uso para el tratamiento de trastornos del sistema nervioso central. | |
| JP2005527593A5 (ru) | ||
| AR067396A1 (es) | Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende | |
| JP2005519083A5 (ru) | ||
| RU2009114167A (ru) | Комбинации специфических ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом | |
| CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
| JP2007500238A5 (ru) | ||
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| RU2006140964A (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| DE60322680D1 (de) | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen | |
| KR20070083826A (ko) | 우울증을 위한 부가 요법 | |
| JP2009541484A (ja) | ５ｈｔ６モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ | |
| ATE453617T1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
| JP2021073171A (ja) | （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物 | |
| JP2007509052A5 (ru) | ||
| RU2011139287A (ru) | Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора | |
| SI1805169T1 (sl) | Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20121016 |